Antibody Therapy for Treating Brain Injury and Preventing Chronic Traumatic Encephalopathy
Repetitive mild traumatic brain injury (rmTBI) is characterized with acute brain dysfunction and can leadto progressive neurodegeneration notably chronic traumatic encephalopathy (CTE). As many as 30%of children engaged in competitive sports will suffer rmTBI. Little is known about the pathogenicchanges that lead from rmTBI to CTE, or whether the general population outside of professionalathletes is at risk for CTE after rmTBI. In prior studies, we have shown that a pathogenic conformationof tau, cis p-tau, is an early marker of injury after rmTBI that mediates and spreads brain damage. Inaddition, we have shown that antibodies targeting cis p-tau prevent long term neurodegeneration aftersingle TBI. Here, we will evaluate preclinical efficacy of cis antibody in stopping brain damage andpreventing CTE after rmTBI, and, if funding available, also develop a human version of our cis antibodythat is needed for clinical trials on TBI patients. We believe that our cis antibody might be rapidlydeveloped to improve the health and life quality of children, athletes and veterans who suffer from rmTBI.